For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$24.54
Thesis
Pfizer is a diversified pharma working through a post-COVID revenue reset and the debt taken on for its $43B Seagen acquisition, which made oncology and antibody-drug conjugates its primary growth engine. The base business — vaccines, internal medicine, and specialty care — generates the cash that funds the pipeline, the dividend, and ongoing cost reductions.
The levers to rebuild growth into the late-2020s patent cliffs are the Seagen oncology pipeline, margin and cost discipline, and an obesity program the company keeps pursuing despite setbacks. The valuation and yield are supported by cash flow, but pipeline productivity and capital-allocation discipline after a string of large deals remain the open questions.
Catalysts
- Seagen oncology / ADC pipeline progression
- Obesity and metabolic program developments
- Cost-cutting and margin recovery
- Late-decade patent-cliff mitigation and BD
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jun 4Trial initiationClinicalTrials.gov
Seagen (Pfizer subsidiary) phase 3 trial (NCT05253651) of tucatinib + trastuzumab + mFOLFOX6 in HER2+ mCRC recruiting
- May 27OtherClinicalTrials.gov
Seagen (Pfizer subsidiary) phase 3 trial NCT06012435 for SGN-B6A vs Docetaxel in NSCLC status updated to ACTIVE_NOT_RECRUITING
- May 11Trial initiationClinicalTrials.gov
Phase 3 trial NCT07566156 (EV-309) of enfortumab vedotin + pembrolizumab vs cCRT in muscle-invasive bladder cancer now recruiting (Astellas sponsor).